A recent study revealed that since January 2015, Senior Health Partners, and at least 2 others, have been systematically cutting home care hours for disabled clients. According to The New York Times, this practice typically occurs without legal justification or proper notice and, by law, only a change in a client’s medical condition or circumstance is supposed to allow a reduction. The study was sponsored by Medicaid Matters and the New York chapter of the National Academy of Elder Law Attorneys. Furthermore, it confirmed similar allegations made in a federal class-action lawsuit filed earlier this year against Senior Health Partners and the New York State Health Department. The lawsuit was on behalf of elderly and disabled clients who were threatened with home care cuts.
The FDA approved the generic versions of the cholesterol lowering drug Crestor, reported The New York Times. Although AstraZeneca attempted to stop cheaper competition from reaching the pharmacy shelves, this new approval will significantly decrease the cost of Crestor and result in a sharp loss of market share for AstraZeneca. Currently, the brand name drug costs about $260 a month, according to GoodRx.com, but with several generics coming onto the market, the price may eventually drop by as much as 80 to 90%.